Send to

Choose Destination
Pharmacogenomics J. 2013 Oct;13(5):389-95. doi: 10.1038/tpj.2013.25. Epub 2013 Jul 16.

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.

Author information

Department of Pharmacy, Scheper Hospital Emmen and Röpcke Zweers Hospital Hardenberg, Emmen, The Netherlands.

Erratum in

  • Pharmacogenomics J. 2014 Aug;14(4):400.


5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center